Immunotech Laboraties, Inc. Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status

Immunotech Laboratories, Inc. (IMMB) today announced the company signed an agreement with The Lebrecht Group, a professional law corporation, to provide legal services for Immunotech and to upgrade the company to OTC:BB fully reporting current status.

Immunotech Founder, President and Chief Science Officer Harry Zhabilov today commented, “This step will help assure our investors and shareholders of the forward progression of Immunotech in both the Medical and Investment communities.”